CULLINAN THERAPEUTICS, INC. (CGEM) Free cash flow 2020–2025
CULLINAN THERAPEUTICS, INC. (CGEM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$175.8MFY2025 · since FY2020: -$29.8M → -$175.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$175.8M | -21.0% |
| FY2024 | -$145.3M | -8.0% |
| FY2023 | -$134.5M | -5.2% |
| FY2022 | -$127.8M | -194.2% |
| FY2021 | -$43.4M | -45.8% |
| FY2020 | -$29.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CGEM financial trends
CGEM RevenueCGEM Net incomeCGEM Net marginCGEM Gross profitCGEM Gross marginCGEM Operating incomeCGEM Operating marginCGEM Operating cash flowCGEM Capital expendituresCGEM Return on equityCGEM Stock buybacksCGEM Dividends paidCGEM Total assetsCGEM Total liabilitiesCGEM Shareholders’ equityCGEM overview →